Impact of RAD51 G135C and XRCC1 Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women

Subtitle:

Article type: Research Article

Authors: Malisic, Emina J.^* | Krivokuca, Ana M. | Boljevic, Ivana Z. | Jankovic, Radmila N.

Affiliations: Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

Correspondence: [*] Corresponding author: Emina Malisic, Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia. Tel.: +381 11 2067 284; Fax: +381 11 2067 294; E-mail:[email protected]

Abstract: OBJECTIVE: The polymorphic variations of DNA repair genes may contribute to functional deficiencies in DNA repair processes increasing susceptibility to cancer. We aimed to investigate the impact of 135G>C RAD51 and XRCC1 Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women. METHODS: The study included 50 ovarian carcinoma samples and 78 cervical swabs of gynecologically healthy age-matched controls. RAD51 G135C and XRCC1 Arg399Gln polymorphisms were determined by PCR-RFLP. Deviations of the genotype frequencies from Hardy-Weinberg equilibrium were assessed using the χ 2 test. The allele- and genotype-specific risks were estimated as odds ratios with 95% confidence intervals. RESULTS: RAD51 135C and XRCC1 Arg allele are associated with ovarian carcinoma [OR (95% CI): 2.54 (1.22-5.29) for C vs. G; 2.64 (1.53-4.55) for Arg vs. Gln]. RAD51 C exerts its effect in dominant (CC plus GC vs. GG) [OR (95% CI): 2.83 (1.21-6.62], while XRCC1Arg in dominant (ArgArg plus ArgGln vs. GlnGln) [OR (95% CI): 4.76 (1.69-13.42)] and recessive model (ArgArg vs. ArgGln plus GlnGln) [OR (95% CI): 2.21 (1.07-4.56)]. CONCLUSION: The results suggest that the RAD51 G135C and XRCC1 Arg399Gln polymorphisms could be biomarkers of susceptibility for ovarian carcinoma development. Further larger case-control study is needed to confirm our findings.

Keywords: DNA repair, ovarian carcinoma, RAD51 G135C polymorphism, XRCC1 Arg399Gln polymorphism

DOI: 10.3233/CBM-150509

Journal: Cancer Biomarkers, vol. 15, no. 5, pp. 685-691, 2015